DLA PIPER LLP (US)

Lobbying for BIOHAVEN PHARMACEUTICALS, INC. · A biopharmaceutical company.

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · Connecticut · House · Senate · $60,000.00 income · posted Oct 17, 2025

Lobbying activity 1

Health Issues

Policies related to drug approval for treatment of rare diseases. Regulatory flexibilities afforded to neurodegenerative diseases as provided for in the Act of ALS.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.